We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-6.58%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.73B
AUM Growth
-$470M
Cap. Flow
-$39.5M
Cap. Flow %
-1.06%
Top 10 Hldgs %
36%
Holding
129
New
6
Increased
41
Reduced
23
Closed
9

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
PEN icon
Penumbra
PEN
+$38.2M
3
BPMC
Blueprint Medicines
BPMC
+$26.6M
4
ABOS icon
Acumen Pharmaceuticals
ABOS
+$17.4M
5
AMGN icon
Amgen
AMGN
+$17M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$44.5M
2
PODD icon
Insulet
PODD
+$40.1M
3
CNMD icon
CONMED
CNMD
+$27.9M
4
ABCM
Abcam PLC
ABCM
+$26M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.04%
2 Consumer Staples 1.17%
3 Industrials 0.83%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OKUR
76
OnKure Therapeutics
OKUR
$162M
$8.71M 0.23%
114,319
– –
PLRX icon
77
Pliant Therapeutics
PLRX
$65.6M
$8.52M 0.23%
491,221
– –
LUNG icon
78
Pulmonx
LUNG
$98.4M
$6.74M 0.18%
652,400
– –
ICVX
79
DELISTED
Icosavax, Inc. Common Stock
ICVX
$6.73M 0.18%
868,409
– –
SGMT icon
80
Sagimet Biosciences
SGMT
$589M
$6.5M 0.17%
+738,355
New +$9.83M
AURA icon
81
Aura Biosciences
AURA
$801M
$6.48M 0.17%
722,896
-296,861
-29% -$3.19M
SPRB
82
Spruce Biosciences
SPRB
$128M
$6.17M 0.17%
36,375
– –
RLAY icon
83
Relay Therapeutics
RLAY
$4.42B
$5.67M 0.15%
673,966
– –
MGNX icon
84
MacroGenics
MGNX
$257M
$5.49M 0.15%
1,178,796
+55,700
+5% +$277K
NVAX icon
85
Novavax
NVAX
$1.29B
$4.69M 0.13%
647,700
+111,000
+21% +$887K
MRSN
86
DELISTED
Mersana Therapeutics
MRSN
$4.32M 0.12%
136,125
– –
CYTK icon
87
Cytokinetics
CYTK
$10.8B
$3.96M 0.11%
134,252
-313,348
-70% -$10.4M
AUPH icon
88
Aurinia Pharmaceuticals
AUPH
$2.06B
$3.73M 0.1%
479,540
– –
FULC icon
89
Fulcrum Therapeutics
FULC
$280M
$3.23M 0.09%
727,673
– –
HCAT icon
90
Health Catalyst
HCAT
$129M
$3.11M 0.08%
307,500
-622,400
-67% -$7.43M
XLO icon
91
Xilio Therapeutics
XLO
$60.4M
$3.04M 0.08%
102,911
– –
GOSS icon
92
Gossamer Bio
GOSS
$86.2M
$2.72M 0.07%
3,266,960
+2,166,686
+197% +$2.5M
BEAM icon
93
Beam Therapeutics
BEAM
$2.77B
$2.68M 0.07%
111,430
– –
VIGL
94
DELISTED
Vigil Neuroscience
VIGL
$2.54M 0.07%
471,958
– –
BMEA icon
95
Biomea Fusion
BMEA
$94.2M
$2.49M 0.07%
181,147
-655,751
-78% -$11.8M
ADAP
96
DELISTED
Adaptimmune Therapeutics
ADAP
$2.17M 0.06%
2,787,845
– –
EPIX
97
DELISTED
ESSA Pharma
EPIX
$2.09M 0.06%
677,005
+13,688
+2% +$39.4K
APLT
98
DELISTED
Applied Therapeutics
APLT
$2.01M 0.05%
808,809
+28,018
+4% +$46.2K
SYRE icon
99
Spyre Therapeutics
SYRE
$8.91B
$1.67M 0.04%
136,556
– –
CYPH
100
Cypherpunk Technologies Inc
CYPH
$71.5M
$1.48M 0.04%
1,074,517
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rock Springs Capital Management held 129 positions worth $3.73B, down 11% from $4.2B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management's Q3 2023 filing shows 6 new, 41 increased, 23 reduced and 9 closed positions. Its largest new stake was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M. The largest sale was argenx, an estimated $44.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2023 buy was Acumen Pharmaceuticals: 2,812,579 shares worth $11.7M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2023, an estimated $46.8M increase.
  • Rock Springs Capital Management's biggest Q3 2023 reduction was argenx, cutting an estimated $44.5M.
  • Rock Springs Capital Management fully exited CONMED in Q3 2023, selling an estimated $27.9M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $3.73B portfolio in Q3 2023.
  • Rock Springs Capital Management opened 6 new positions and closed 9 in Q3 2023.
  • Rock Springs Capital Management's portfolio value fell 11% quarter-over-quarter to $3.73B.

Based on Rock Springs Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.